Lurasidone
- Generic Name
- Lurasidone
- Brand Names
- Latuda
- Drug Type
- Small Molecule
- Chemical Formula
- C28H36N4O2S
- CAS Number
- 367514-87-2
- Unique Ingredient Identifier
- 22IC88528T
- Background
Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States.
- Indication
Lurasidone is indicated for the treatment of schizophrenia in patients ≥13 years old. It is also indicated as a monotherapy for the treatment of bipolar depression in patients ≥10 years old, or in combination with lithium or valproate for the treatment of bipolar depression in adults.
- Associated Conditions
- Depression, Bipolar, Schizophrenia
- Associated Therapies
- -
Digoxin Drug-Drug Interaction With Lurasidone HCl
- Conditions
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01082289
- Locations
- 🇺🇸
California Clinical Trials, Culver City, California, United States
RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE
- First Posted Date
- 2010-03-08
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01082146
- Locations
- 🇺🇸
Covance Global Clinical Research Unit Inc., Madison, Wisconsin, United States
Lithium Drug-Drug Interaction Study With Lurasidone HCl
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01074073
- Locations
- 🇺🇸
CCT/Parexel, Culver City, California, United States
Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl
- Conditions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2011-09-08
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01074632
- Locations
- 🇺🇸
Clinical Research Institute, Wichita, Kansas, United States
🇺🇸California Clinical Trials, Glendale, California, United States
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 817
- Registration Number
- NCT00868959
- Locations
- 🇺🇸
Clinical Innovations Inc., Santa Ana, California, United States
🇺🇸Accurate Clinical Trials, Kissimmee, Florida, United States
🇺🇸Sheppard Pratt Health System, Baltimore, Maryland, United States
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 505
- Registration Number
- NCT00868699
- Locations
- 🇺🇸
CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States
🇺🇸Mood Disorders Program-UHCMC, Cleveland, Ohio, United States
🇮🇳R.K. Yadav Memorial Mental Health & De-Addiction Hospital, Jaipur, Rajasthan, India
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 488
- Registration Number
- NCT00790192
- Locations
- 🇺🇸
CNRI-Los Angeles. LLC, Pico Rivera, California, United States
🇺🇸Florida Clinical Research Center, Bradenton, Florida, United States
🇷🇴Spitalul de Psihiatrie Titan "Dr. Constantin Gorgos", Bdul Nicolae Grigorescu nr. 41, Bucuresti, Romania
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 629
- Registration Number
- NCT00641745
- Locations
- 🇺🇸
K&S Professional Research Services LLC, Little Rock, Arkansas, United States
🇺🇸Woodland International Research Group, LLC, Little Rock, Arkansas, United States
🇺🇸Fidelity Clinical Research Inc., North Miami, Florida, United States
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 478
- Registration Number
- NCT00615433
- Locations
- 🇺🇸
Lousiana Clinical Research, LLC, Shreveport, Louisiana, United States
🇺🇸UCSD Medical Center, San Diego, California, United States
🇺🇸Clinical Pharmacological Studies, Inc., Cerritos, California, United States
Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia
- First Posted Date
- 2007-10-26
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 489
- Registration Number
- NCT00549718
- Locations
- 🇺🇸
Clinical Innovations, Inc., Costa Mesa, California, United States
🇺🇸Collaborative Neuroscience Network Inc.,12772 Valley View Street,Suite 3, Garden Grove, California, United States
🇺🇸Center for Behavioral Health, LLC, Rockville, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.